# Pelagos Insurance Capital Limited share price today (Pelagos Insurance Capital Limited, PLGO)

> Pelagos Insurance Capital Limited's earnings have grown faster than its share price. Earnings per share grew +115.3% in a year while the price moved +45.4%. PLGO · Financials · Insurance - Diversified · data as of 4 November 2026. Page: https://www.sectoralpha.in/us/stocks/plgo

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Turning around, from the last 12 quarters
- Price: $27.42 (+45.4% in a year)
- P/BV: 1.0× (higher than 100% of the last 3.3 years)
- Revenue (Jun 2026): $650 M (+10.3% on a year ago)
- Profit (Jun 2026): $44.4 M (+125.4% on a year ago)
- Net margin: 6.8% (+3.5 points on a year ago)
- ROE: 18%, FY25
- ROA: 2.41%, latest

The main question: yearly earnings per share moved +115.3% while the share price moved +45.4%. ## What is the Pelagos Insurance Capital Limited share price today? Pelagos Insurance Capital Limited's share price was $27.42 at the close on 4 November 2026. It has been rising for 43 weeks. That is 21.9% above its average price over the last 200 trading days. In the last 52 weeks it traded between $18 and $27, and at that close it was at the high of that range. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 2 weeks in a row. Over the last 3.3 years the share price moved +101% while the S&P 500 moved +73%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Pelagos Insurance Capital Limited pay? Pelagos Insurance Capital Limited paid $0.60 per share over the last four reported quarters. The most recent declaration was $0.15 for Jun 2026. At today's price of $27.42 that is a yield of 2.19%, based on dividends already paid, not a forecast. ## Which stock lists is Pelagos Insurance Capital Limited on? Pelagos Insurance Capital Limited is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Pelagos Insurance Capital Limited profitable? Pelagos Insurance Capital Limited earned $44.4 M of net profit in the Jun 2026 quarter, +125.4% on the same quarter a year earlier. Full-year FY25 profit was $226 M. Over 4 years profit has grown 34.8% a year on average. That is 6.8% of the quarter's revenue. The same quarter a year earlier earned $19.7 M. 2 of the last 12 reported quarters were loss-making. For the full year, FY25 profit was $226 M (+99.0% on the year before). ## How much revenue does Pelagos Insurance Capital Limited make, and is it growing? Pelagos Insurance Capital Limited reported $650 M of income in the Jun 2026 quarter, +10.3% on the same quarter a year earlier. Over 4 years it has grown 20.3% a year on average. The last full year, FY25, came in at $2.5 B. The last four reported quarters add to $2.5 B. FY25 revenue was $2.5 B, +3.3% on the year before. Recent pace: the last four quarters grew −3.2% on average, against 20.3% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −3.6%, against +8.1% a year over the last 8 quarters (rolling over). ## How much does Pelagos Insurance Capital Limited keep from what it earns? Pelagos Insurance Capital Limited's net margin was 6.8% in the Jun 2026 quarter, 3.5 percentage points higher than the same quarter a year ago. Across 5 years it has been between 3.5% and 109.0%. The latest quarter is within that range. Why: the net margin move is clear, but the cost details behind it are not in our data, so we show the move without guessing the reason. ## How many of Pelagos Insurance Capital Limited's loans have gone bad? Pelagos Insurance Capital Limited does not report loan-quality figures this page can read, so this section says so rather than guess. No bad-loan figures are filed in a form this page can read, and none are guessed from the profit line. The income, margin and return sections carry what this business does report. Why: loan quality drives a lender, but its details (new bad loans, recoveries, money set aside) are not in our data for this company. The sections around this one carry what we can back up. ## How fast is Pelagos Insurance Capital Limited's loan book growing? Pelagos Insurance Capital Limited's revenue was $2.5 B in FY25, +3.3% on the year before, so the loan book is growing. The latest quarter was +10.3% on a year earlier. The net margin on that income is 6.8%, +3.5 percentage points on a year ago. Interest income stands in for the size of the loan book; changes in interest rates can move it a few points in any year. In short: a lender grows well when its loan book grows, its margin stays steady and its loans stay clean. Quarterly loan-quality figures are missing here, so revenue growth and margin are the two we watch. ## What is Pelagos Insurance Capital Limited's P/BV ratio, and how does it compare with its own history? Pelagos Insurance Capital Limited's P/BV is 1.0×, about the highest it has ever been. Its usual P/BV (the middle reading) is 0.8×, over 3.3 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year book value grew while the price moved +45.4%. The price ran ahead of book value, which pushed the multiple up within its own range. Where the price move came from: over 3 years the price moved +24.6% a year; about +13.6% a year came from book-value growth and about +11.0 percentage points from the multiple (the market paying more). The split is approximate (price return minus book-value growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the book value trend underneath matters more than the multiple. ## Is the Pelagos Insurance Capital Limited business getting better or worse? Pelagos Insurance Capital Limited's business is turning around. Profit growth has swung from −103.1% at its low to +99.0%, rising from a low 1 quarters ago, with ROE rising at 18.0%. This is based on 11 quarters of 4 measures. Why it matters: a turn in growth is often where a bigger change starts. The lines say a turn is forming, so the question is whether the next quarters confirm it. ## How much does Pelagos Insurance Capital Limited earn on its equity and assets? Pelagos Insurance Capital Limited earned a return on equity of 9% in FY25. Its lowest yearly reading on file was 3% in FY22. On its assets, every $100 earned about $2.41, before the effect of borrowing. For a lender the balance sheet is the business, so the return on equity and on assets have to be read together. That return is below the level a bank needs to grow its net worth quickly, which helps explain why its multiple is where it is. Why ROE moved: profit grew 34.8% a year over 4 years while net worth grew more slowly. When earnings recover faster than net worth builds up, ROE climbs off its low. ## Does Pelagos Insurance Capital Limited have too much debt? For a bank, borrowing is the raw material of the business, not a warning sign: it borrows money in order to lend it out. Its safety is read through its returns and its loans. Its safety is read from the bad-loan figures and the return on equity instead. For a manufacturer, debt is a claim on its profits. For a lender it is the stock it trades in, so the usual debt-to-equity test would mislead and is not used here. ## What is the Pelagos Insurance Capital Limited shareholding pattern? 6.3% of Pelagos Insurance Capital Limited's tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 5.6 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Pelagos Insurance Capital Limited from balance-sheet trouble? For Pelagos Insurance Capital Limited, the Z-score is not used, because it was built for manufacturers, not lenders. For a lender, safety is read from its capital and bad-loan figures instead. ## How does Pelagos Insurance Capital Limited rank in its industry? 67.5 out of 100, rank 3 of 10 in Insurance - Diversified, with 69% of the evidence available. Pelagos Insurance Capital Limited scores 67.5 out of 100 against the 10 companies it is compared with in Insurance - Diversified, ranking 3. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 18.8 + 15.4 + 16.2 + 17.1 = 67.5. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if ROA turns down or gross NPA rises while the share price lags its sector. ## Which companies is Pelagos Insurance Capital Limited compared with? Pelagos Insurance Capital Limited ranks 3 of 10 Insurance - Diversified companies on the 4-Factor Sector Score, with 67.5 out of 100. 1. [Exzeo Group, Inc.](https://www.sectoralpha.in/us/stocks/xzo) XZO · turning · Most evidence points up · 74% evidence 70.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.0/35 · Income 25% · Profit 52.7% · 81% evidence Capital efficiency 19.9/25 · ROA 19% · ROE 30.9% · GNPA n/a · 68% evidence Valuation 8.1/20 · P/BV 5.32× · P/BV÷ROE 0.17 · 70% evidence Relative strength 14.6/20 · Lead over its industry 8.6% · Lead over S&P 500 8.1% · 1 year -0.3% · 70% evidence · 8 of 12 weeks ahead Exact sum: 28 + 19.9 + 8.1 + 14.6 = 70.6 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Arch Capital Group Ltd.](https://www.sectoralpha.in/us/stocks/acgl) ACGL · turning · Most evidence points up · 80% evidence 70.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.3/35 · Income 0.4% · Profit 25.9% · 81% evidence Capital efficiency 18.6/25 · ROA 3.6% · ROE 17.3% · GNPA n/a · 68% evidence Valuation 14.9/20 · P/BV 1.41× · P/BV÷ROE 0.08 · 70% evidence Relative strength 15.5/20 · Lead over its industry 7.4% · Lead over S&P 500 7.4% · 1 year 23.6% · 100% evidence · 2 of 12 weeks ahead Exact sum: 21.3 + 18.6 + 14.9 + 15.5 = 70.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. Pelagos Insurance Capital Limited this page PLGO · turning · Most evidence points up · 69% evidence 67.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.8/35 · Income -3.6% · Profit n/a · 52% evidence Capital efficiency 15.4/25 · ROA 2.3% · ROE 18.6% · GNPA n/a · 68% evidence Valuation 16.2/20 · P/BV 0.94× · P/BV÷ROE 0.05 · 70% evidence Relative strength 17.1/20 · Lead over its industry 17.5% · Lead over S&P 500 17.9% · 1 year 45.4% · 100% evidence · 3 of 12 weeks ahead Exact sum: 18.8 + 15.4 + 16.2 + 17.1 = 67.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. Berkshire Hathaway Inc. BRK-A · breaking out · Evidence leans up · 80% evidence 60.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.3/35 · Income 3.9% · Profit 36.3% · 81% evidence Capital efficiency 11.5/25 · ROA 2.7% · ROE 5.6% · GNPA n/a · 68% evidence Valuation 5.7/20 · P/BV 1.44× · P/BV÷ROE 0.26 · 70% evidence Relative strength 19.0/20 · Lead over its industry 8.9% · Lead over S&P 500 8.9% · 1 year 16.3% · 100% evidence · 4 of 12 weeks ahead Exact sum: 24.3 + 11.5 + 5.7 + 19 = 60.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [The Hartford Insurance Group, Inc.](https://www.sectoralpha.in/us/stocks/hig) HIG · basing · Evidence leans up · 80% evidence 57.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.9/35 · Income 7% · Profit 34.7% · 81% evidence Capital efficiency 17.5/25 · ROA 3% · ROE 17% · GNPA n/a · 68% evidence Valuation 12.6/20 · P/BV 1.85× · P/BV÷ROE 0.11 · 70% evidence Relative strength 3.8/20 · Lead over its industry -4.4% · Lead over S&P 500 -4.5% · 1 year 6.7% · 100% evidence · 1 of 12 weeks ahead Exact sum: 23.9 + 17.5 + 12.6 + 3.8 = 57.8 · What this means: Earnings are strong; relative strength in its sector is -4.4% and the one-year return is 6.7%. 6. [Aegon Ltd.](https://www.sectoralpha.in/us/stocks/aeg) AEG · quiet · Too little evidence to rank firmly · 56% evidence 56.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.5/35 · Income n/a · Profit n/a · 15% evidence Capital efficiency 15.8/25 · ROA 2.3% · ROE 76.9% · GNPA n/a · 68% evidence Valuation 16.3/20 · P/BV 1.25× · P/BV÷ROE 0.02 · 70% evidence Relative strength 5.1/20 · Lead over its industry -1.6% · Lead over S&P 500 -1.4% · 1 year 12.9% · 100% evidence · 3 of 12 weeks ahead Exact sum: 19.5 + 15.8 + 16.3 + 5.1 = 56.7 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 7. [American International Group, Inc.](https://www.sectoralpha.in/us/stocks/aig) AIG · turning · Evidence leans down · 80% evidence 41.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 12.3/35 · Income -2.4% · Profit -7.3% · 81% evidence Capital efficiency 10.7/25 · ROA 1.9% · ROE 7.5% · GNPA n/a · 68% evidence Valuation 8.6/20 · P/BV 0.97× · P/BV÷ROE 0.13 · 70% evidence Relative strength 9.9/20 · Lead over its industry -1.3% · Lead over S&P 500 -1.4% · 1 year 6.2% · 100% evidence · 0 of 12 weeks ahead Exact sum: 12.3 + 10.7 + 8.6 + 9.9 = 41.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [International General Insurance Holdings Ltd.](https://www.sectoralpha.in/us/stocks/igic) IGIC · quiet · Evidence leans down · 80% evidence 37.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 9.9/35 · Income -1.9% · Profit -13.6% · 81% evidence Capital efficiency 15.6/25 · ROA 2.9% · ROE 12.7% · GNPA n/a · 68% evidence Valuation 11.5/20 · P/BV 1.64× · P/BV÷ROE 0.13 · 70% evidence Relative strength 0.5/20 · Lead over its industry -10.1% · Lead over S&P 500 -10.1% · 1 year 10.7% · 100% evidence · 1 of 12 weeks ahead Exact sum: 9.9 + 15.6 + 11.5 + 0.5 = 37.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Sun Life Financial Inc.](https://www.sectoralpha.in/us/stocks/slf) SLF · turning · Evidence leans down · 80% evidence 35.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 11.6/35 · Income 4.1% · Profit 2.2% · 81% evidence Capital efficiency 7.5/25 · ROA 0.5% · ROE 7.4% · GNPA n/a · 68% evidence Valuation 3.8/20 · P/BV 2.31× · P/BV÷ROE 0.31 · 70% evidence Relative strength 12.3/20 · Lead over its industry 7.7% · Lead over S&P 500 8.1% · 1 year 40.1% · 100% evidence · 3 of 12 weeks ahead Exact sum: 11.6 + 7.5 + 3.8 + 12.3 = 35.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Brookfield Wealth Solutions Ltd.](https://www.sectoralpha.in/us/stocks/bnt) BNT · basing · Most evidence points down · 68% evidence 21.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 3.8/35 · Income -17.5% · Profit -84.2% · 81% evidence Capital efficiency 4.3/25 · ROA -0.4% · ROE -13.8% · GNPA n/a · 68% evidence Valuation 9.8/20 · P/BV 0.8× · P/BV÷ROE n/a · 10% evidence Relative strength 3.6/20 · Lead over its industry -7% · Lead over S&P 500 -7.2% · 1 year -5.8% · 100% evidence · 0 of 12 weeks ahead Exact sum: 3.8 + 4.3 + 9.8 + 3.6 = 21.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. Financial companies use P/BV÷ROE and asset quality; PEG, industrial OPM and ROCE are excluded. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Jun 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Insurance - Diversified](https://www.sectoralpha.in/us/sectors/insurance-diversified), all 10 compared on one page. ## Which companies are close to Pelagos Insurance Capital Limited in size? Pelagos Insurance Capital Limited is the 8th largest of 11 Insurance - Diversified companies on Sector Alpha by market value (scores of 4 November 2026). Just above it: Arch Capital Group, Brookfield Wealth Solutions and Aegon. Just below it: Exzeo Group, Inc., International General Insurance Holdings and Waterdrop Inc. ### Insurance - Diversified companies close in size

1. [Arch Capital Group Ltd.](https://www.sectoralpha.in/us/stocks/acgl) $36 billion
2. [Brookfield Wealth Solutions Ltd.](https://www.sectoralpha.in/us/stocks/bnt) $15.4 billion
3. [Aegon Ltd.](https://www.sectoralpha.in/us/stocks/aeg) $12.8 billion
4. Pelagos Insurance Capital Limited $2.3 billion
5. [Exzeo Group, Inc.](https://www.sectoralpha.in/us/stocks/xzo) $1.7 billion
6. [International General Insurance Holdings Ltd.](https://www.sectoralpha.in/us/stocks/igic) $1 billion
7. [Waterdrop Inc.](https://www.sectoralpha.in/us/stocks/wdh) $363 million

[All 11 Insurance - Diversified companies, largest first](https://www.sectoralpha.in/us/sectors/insurance-diversified#all-companies)

### Companies close in size in other industries

1. [The Boston Beer Company, Inc.](https://www.sectoralpha.in/us/stocks/sam) $2.3 billion · Beverages - Brewers
2. [Intuitive Machines, Inc.](https://www.sectoralpha.in/us/stocks/lunr) $2.3 billion · Aerospace & Defense
3. Pelagos Insurance Capital Limited $2.3 billion
4. [Septerna, Inc.](https://www.sectoralpha.in/us/stocks/sepn) $2.2 billion · Biotechnology
5. [Trulieve Cannabis Corp.](https://www.sectoralpha.in/us/stocks/trlv) $2.2 billion · Drug Manufacturers - Specialty & Generic

## What else do people ask about Pelagos Insurance Capital Limited? ### What were Pelagos Insurance Capital Limited Limited's latest quarterly results? Pelagos Insurance Capital Limited reported total income of $650 M and net profit of $44.4 M for the Jun 2026 quarter. Income rose 10.3% and profit rose 125.4% compared with a year earlier. Earnings per share were $0.52 (as of 4 November 2026). ### What is Pelagos Insurance Capital Limited Limited's market cap? Pelagos Insurance Capital Limited's market capitalisation is $2.3 B at a stock price of $27.42. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Pelagos Insurance Capital Limited Limited performing? Pelagos Insurance Capital Limited's share price has been rising for 43 weeks. In its latest quarter, income rose 10.3% and profit rose 125.4% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 2 weeks running (as of 4 November 2026). ### Will Pelagos Insurance Capital Limited Limited's stock price go up? This page does not forecast Pelagos Insurance Capital Limited's stock price. What it shows instead: the stock price is $27.42, and it has been rising for 43 weeks. Its P/BV of 1.0× is higher than 100% of its own last 3 years (as of 4 November 2026). ### Where is Pelagos Insurance Capital Limited Limited in its business cycle? Pelagos Insurance Capital Limited's FY25 net margin was 9.0%, against a 5-year range of 3.5% to 109.0%: the low end of its own range, which is often where recoveries start. The latest quarter was 6.8%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the Pelagos Insurance Capital Limited Limited story? The main question: yearly earnings per share moved +115.3% while the share price moved +45.4%. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Pelagos Insurance Capital Limited Limited a stock worth studying right now? What the numbers show: Pelagos Insurance Capital Limited's earnings have grown faster than its share price. Earnings per share grew +115.3% in a year while the price moved +45.4%. The main open question: whether the price catches up with earnings that have already grown. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). This is research, not advice. We’re not SEBI-registered.